glp-1 compounding filter types Microdosing and Custom Dosing Non-Traditional Channels: The Compounded GLP-1

Imataka, K

3 GLP-1RAs stimulate glucose-dependent insulin secretion, suppress glucagon release, and slow gastric emptying, which improves postprandial blood glucose levels

This type of optionality may provide additional long-term strategic value if regulatory environments surrounding psychedelic-based therapies continue to evolve favorably

If clinically effective, this modality could lower treatment barriers associated with injectable insulin and delay progression to advanced disease stages

Post-marketing surveillance and FDA Adverse Event Reporting System (FAERS) data have documented isolated reports of patients experiencing dyspnea while taking GLP-1 medications, but establishing causality remains challenging